{"filing":{"accession_number":"0001731122-26-001143","cik":"0001314052","ticker":"AVXL","company_name":"ANAVEX LIFE SCIENCES CORP.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-25","primary_document":"e7897_8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1314052/000173112226001143/e7897_8-k.htm"},"events":[{"id":29349,"run_id":26867,"accession_number":"0001731122-26-001143","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q3 fiscal 2026 (quarter ended June 30, 2026) issued on August 25, 2026. The press release reports financial results including consolidated statements of operations, balance sheet data, and per-share metrics (net income of $0.08 per share vs. net loss of $0.16 per share in the prior year quarter). The filing explicitly states the press release was \"issued\" on August 25, 2026 and is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases.","company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31601,"accession_number":"0001731122-26-001143","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q3 fiscal 2026 (quarter ended June 30, 2026) issued on August 25, 2026. The press release reports financial results including consolidated statements of operations, balance sheet data, and per-share metrics (net income of $0.08 per share vs. net loss of $0.16 per share in the prior year quarter). The filing explicitly states the press release was \"issued\" on August 25, 2026 and is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T12:32:53.156767+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31601,"accession_number":"0001731122-26-001143","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q3 fiscal 2026 (quarter ended June 30, 2026) issued on August 25, 2026. The press release reports financial results including consolidated statements of operations, balance sheet data, and per-share metrics (net income of $0.08 per share vs. net loss of $0.16 per share in the prior year quarter). The filing explicitly states the press release was \"issued\" on August 25, 2026 and is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T12:32:53.156767+00:00","company_name":"ANAVEX LIFE SCIENCES CORP.","ticker":"AVXL","filing_date":"2026-08-25"}]}